Chuu Chih-Pin, Chen Rou-Yu, Kokontis John M, Hiipakka Richard A, Liao Shutsung
The Ben May Department for Cancer Research, The University of Chicago, 929 East 57th Street, CIS W325F, Chicago, IL 60637, USA.
Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1.
The green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), inhibits the development and progression of prostate cancer in TRAMP mice and in men. We examined the effects of EGCG on LNCaP human prostate cancer sublines 104-S, 104-R1 and R1Ad representing different progression stages of prostate cancer. EGCG suppressed cell proliferation, prostate specific antigen (PSA) expression, and AR transcriptional activity in the different LNCaP sublines. Intraperitoneal administration of EGCG also suppressed the growth of relapsing R1Ad tumors and decreased tumor-derived serum PSA. Effects of EGCG on tumor PSA expression have the potential to affect accurate monitoring of patient tumor burden by serum PSA measurements.
绿茶多酚(-)-表没食子儿茶素-3-没食子酸酯(EGCG)可抑制TRAMP小鼠和男性前列腺癌的发生和发展。我们研究了EGCG对代表前列腺癌不同进展阶段的LNCaP人前列腺癌亚系104-S、104-R1和R1Ad的影响。EGCG抑制了不同LNCaP亚系中的细胞增殖、前列腺特异性抗原(PSA)表达和AR转录活性。腹腔注射EGCG还抑制了复发性R1Ad肿瘤的生长,并降低了肿瘤来源的血清PSA。EGCG对肿瘤PSA表达的影响有可能影响通过血清PSA测量对患者肿瘤负荷的准确监测。